This site is intended for healthcare professionals

FDA approves expansion of indication for Enhertu in metastatic HER2-positive gastric or gastroesophageal adenocarcinoma.- AstraZeneca/Daiichi Sankyo

Read time: 1 mins
Last updated:17th Jan 2021
Published:17th Jan 2021
Condition: Gastric Cancer/Stomach Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest